{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:01:16Z","timestamp":1784678476407,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["AR073233"],"award-info":[{"award-number":["AR073233"]}]},{"name":"NCI","award":["P30CA014089"],"award-info":[{"award-number":["P30CA014089"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02956-3","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:27:34Z","timestamp":1779780454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["VprBP drives prostate tumorigenesis by its kinase activity targeting histone H2A"],"prefix":"10.1186","volume":"24","author":[{"given":"Sungmin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil B.","family":"Ghate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woojin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"10","key":"2956_CR1","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s11912-025-01686-y","volume":"27","author":"EH Bent","year":"2025","unstructured":"Bent EH, Morris MJ. Prostate cancer radioligand therapy: PSMA and beyond, current landscape and future directions. Curr Oncol Rep. 2025;27(10):1170\u201384.","journal-title":"Curr Oncol Rep"},{"key":"2956_CR2","doi-asserted-by":"publisher","first-page":"oyaf095","DOI":"10.1093\/oncolo\/oyaf095","volume":"30","author":"C Avila","year":"2025","unstructured":"Avila C, Gonzalez-Montero J, Rojas CI, Madan RA, Burotto M. Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: a cost-effectiveness focused review. Oncologist. 2025;30:oyaf095.","journal-title":"Oncologist"},{"key":"2956_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14737140.2025.2509760","volume":"25","author":"G Ingrosso","year":"2025","unstructured":"Ingrosso G, Lancia A, Bardoscia L, Becherini C, Bottero M, Bertini N, et al. Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer. Expert Rev Anticancer Ther. 2025;25:741\u201354.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2956_CR4","first-page":"82","volume":"6","author":"U Testa","year":"2019","unstructured":"Testa U, Castelli G, Pelosi E. Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications. Medicines (Basel). 2019;6:82.","journal-title":"Medicines (Basel)"},{"key":"2956_CR5","doi-asserted-by":"publisher","first-page":"e000717","DOI":"10.1136\/bmjonc-2024-000717","volume":"4","author":"F Urabe","year":"2025","unstructured":"Urabe F, Takemura K. Evaluating the genetic landscape of prostate cancer: new insights from BRCA1\/2, ATM and CDK12 mutations. BMJ Oncol. 2025;4:e000717.","journal-title":"BMJ Oncol"},{"key":"2956_CR6","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.3390\/ijms26157475","volume":"26","author":"Y Fatima","year":"2025","unstructured":"Fatima Y, Jobre KN, Gomez-Gomez E, Malkiewicz B, Vlahou A, Mokou M, et al. Omics-mediated treatment for advanced prostate cancer: moving towards precision oncology. Int J Mol Sci. 2025;26:7475.","journal-title":"Int J Mol Sci"},{"key":"2956_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.path.2024.10.001","volume":"18","author":"CC Ding","year":"2025","unstructured":"Ding CC, Greenland NY, Sirohi D, Lotan TL. Molecular landscape of aggressive histologic subtypes of localized prostate cancer. Surg Pathol Clin. 2025;18:1\u201312.","journal-title":"Surg Pathol Clin"},{"key":"2956_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-1-4939-1804-1_11","volume":"1238","author":"TC McKee","year":"2015","unstructured":"McKee TC, Tricoli JV. Epigenetics of prostate cancer. Methods Mol Biol. 2015;1238:217\u201334.","journal-title":"Methods Mol Biol"},{"key":"2956_CR9","first-page":"341","volume":"5","author":"K Jones","year":"2021","unstructured":"Jones K, Zhang Y, Kong Y, Farah E, Wang R, Li C, et al. Epigenetics in prostate cancer treatment. J Transl Genet Genom. 2021;5:341\u201356.","journal-title":"J Transl Genet Genom"},{"key":"2956_CR10","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.21037\/tau-20-1339","volume":"10","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Epigenetics in prostate cancer: clinical implications. Transl Androl Urol. 2021;10:3104\u201316.","journal-title":"Transl Androl Urol"},{"key":"2956_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/1008-682X.179859","volume":"18","author":"S Yegnasubramanian","year":"2016","unstructured":"Yegnasubramanian S. Prostate cancer epigenetics and its clinical implications. Asian J Androl. 2016;18:549\u201358.","journal-title":"Asian J Androl"},{"key":"2956_CR12","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.3390\/cancers15225325","volume":"15","author":"MA Hussein","year":"2023","unstructured":"Hussein MA, Munirathinam G. Gene Expression and DNA methylation as prognostic markers in metastatic castration-resistant prostate cancer: analysis of circulating tumor cells and paired plasma-derived exosomes. Cancers (Basel). 2023;15:5325.","journal-title":"Cancers (Basel)"},{"key":"2956_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.21037\/tau-24-382","volume":"14","author":"F Barletta","year":"2025","unstructured":"Barletta F, Bandini M, Cirulli GO, Zaurito P, Luciano R, Giannese F, et al. DNA methylation alterations in prostate cancer: from diagnosis to treatment. Transl Androl Urol. 2025;14:454\u201362.","journal-title":"Transl Androl Urol"},{"key":"2956_CR14","doi-asserted-by":"publisher","first-page":"7172","DOI":"10.18632\/oncotarget.2262","volume":"5","author":"S Chinaranagari","year":"2014","unstructured":"Chinaranagari S, Sharma P, Chaudhary J. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer. Oncotarget. 2014;5:7172\u201382.","journal-title":"Oncotarget"},{"key":"2956_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4161\/epi.24532","volume":"8","author":"G Deb","year":"2013","unstructured":"Deb G, Thakur VS, Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics. 2013;8:464\u201376.","journal-title":"Epigenetics"},{"key":"2956_CR16","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1038\/s41598-019-40238-w","volume":"9","author":"R Zhou","year":"2019","unstructured":"Zhou R, Yang Y, Park SY, Seo YW, Jung SC, Kim KK, et al. p300\/CBP-associated factor promotes autophagic degradation of delta-catenin through acetylation and decreases prostate cancer tumorigenicity. Sci Rep. 2019;9:3351.","journal-title":"Sci Rep"},{"key":"2956_CR17","first-page":"7638","volume":"63","author":"JD Debes","year":"2003","unstructured":"Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res. 2003;63:7638\u201340.","journal-title":"Cancer Res"},{"key":"2956_CR18","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2956_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/cc.6.2.3732","volume":"6","author":"E Le Rouzic","year":"2007","unstructured":"Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, et al. HIV1 Vpr arrests the cell cycle by recruiting DCAF1\/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle. 2007;6:182\u20138.","journal-title":"Cell Cycle"},{"key":"2956_CR20","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1038\/onc.2008.44","volume":"27","author":"J Huang","year":"2008","unstructured":"Huang J, Chen J. VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation. Oncogene. 2008;27:4056\u201364.","journal-title":"Oncogene"},{"key":"2956_CR21","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1128\/MCB.00232-08","volume":"28","author":"CM McCall","year":"2008","unstructured":"McCall CM, Miliani de Marval PL, Chastain PD 2nd, Jackson SC, He YJ, Kotake Y, et al. Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. Mol Cell Biol. 2008;28:5621\u201333.","journal-title":"Mol Cell Biol"},{"key":"2956_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0378-1119(00)00583-7","volume":"263","author":"S Zhang","year":"2001","unstructured":"Zhang S, Feng Y, Narayan O, Zhao LJ. Cytoplasmic retention of HIV-1 regulatory protein Vpr by protein-protein interaction with a novel human cytoplasmic protein VprBP. Gene. 2001;263:131\u201340.","journal-title":"Gene"},{"key":"2956_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1128\/MCB.06037-11","volume":"32","author":"K Kim","year":"2012","unstructured":"Kim K, Heo K, Choi J, Jackson S, Kim H, Xiong Y, et al. Vpr-binding protein antagonizes p53-mediated transcription via direct interaction with H3 tail. Mol Cell Biol. 2012;32:783\u201396.","journal-title":"Mol Cell Biol"},{"key":"2956_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.molcel.2013.09.017","volume":"52","author":"K Kim","year":"2013","unstructured":"Kim K, Kim JM, Kim JS, Choi J, Lee YS, Neamati N, et al. VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. Mol Cell. 2013;52:459\u201367.","journal-title":"Mol Cell"},{"key":"2956_CR25","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.3390\/biomedicines11092552","volume":"11","author":"Y Shin","year":"2023","unstructured":"Shin Y, Kim S, Liang G, Ulmer TS, An W. VprBP\/DCAF1 triggers melanomagenic gene silencing through histone H2A phosphorylation. Biomedicines. 2023;11:2552.","journal-title":"Biomedicines"},{"key":"2956_CR26","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1002\/1878-0261.13068","volume":"15","author":"NB Ghate","year":"2021","unstructured":"Ghate NB, Kim S, Spiller E, Kim S, Shin Y, Rhie SK, et al. VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer. Mol Oncol. 2021;15:2801\u201317.","journal-title":"Mol Oncol"},{"key":"2956_CR27","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/s41467-023-37883-1","volume":"14","author":"NB Ghate","year":"2023","unstructured":"Ghate NB, Kim S, Shin Y, Kim J, Doche M, Valena S, et al. Phosphorylation and stabilization of EZH2 by DCAF1\/VprBP trigger aberrant gene silencing in colon cancer. Nat Commun. 2023;14:2140.","journal-title":"Nat Commun"},{"key":"2956_CR28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41388-023-02685-8","volume":"42","author":"NB Ghate","year":"2023","unstructured":"Ghate NB, Kim S, Mehmood R, Shin Y, Kim K, An W. VprBP\/DCAF1 regulates p53 function and stability through site-specific phosphorylation. Oncogene. 2023;42:1405\u201316.","journal-title":"Oncogene"},{"key":"2956_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13072-024-00561-7","volume":"17","author":"Y Shin","year":"2024","unstructured":"Shin Y, Kim S, Choi TI, Kim CH, An W. VprBP regulates osteoclast differentiation via an epigenetic mechanism involving histone H2A phosphorylation. Epigenetics Chromatin. 2024;17:35.","journal-title":"Epigenetics Chromatin"},{"key":"2956_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1101\/gad.268714.115","volume":"30","author":"K Kim","year":"2016","unstructured":"Kim K, Punj V, Kim JM, Lee S, Ulmer TS, Lu W, et al. MMP-9 facilitates selective proteolysis of the histone H3 tail at genes necessary for proficient osteoclastogenesis. Genes Dev. 2016;30:208\u201319.","journal-title":"Genes Dev"},{"key":"2956_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13072-018-0193-1","volume":"11","author":"K Kim","year":"2018","unstructured":"Kim K, Shin Y, Kim J, Ulmer TS, An W. H3K27me1 is essential for MMP-9-dependent H3N-terminal tail proteolysis during osteoclastogenesis. Epigenetics Chromatin. 2018;11:23.","journal-title":"Epigenetics Chromatin"},{"key":"2956_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/minf.201200141","volume":"32","author":"M Reutlinger","year":"2013","unstructured":"Reutlinger M, Koch CP, Reker D, Todoroff N, Schneider P, Rodrigues T, et al. Chemically advanced template search (CATS) for scaffold-hopping and prospective target prediction for \u201corphan\u201d molecules. Mol Inform. 2013;32:133\u20138.","journal-title":"Mol Inform"},{"key":"2956_CR33","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/nprot.2007.202","volume":"2","author":"D Shechter","year":"2007","unstructured":"Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protoc. 2007;2:1445\u201357.","journal-title":"Nat Protoc"},{"key":"2956_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13072-019-0270-0","volume":"12","author":"Y Shin","year":"2019","unstructured":"Shin Y, Ghate NB, Moon B, Park K, Lu W, An W. DNMT and HDAC inhibitors modulate MMP-9-dependent H3 N-terminal tail proteolysis and osteoclastogenesis. Epigenetics Chromatin. 2019;12:25.","journal-title":"Epigenetics Chromatin"},{"key":"2956_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41388-021-02109-5","volume":"41","author":"Y Shin","year":"2022","unstructured":"Shin Y, Kim S, Ghate NB, Rhie SK, An W. MMP-9 drives the melanomagenic transcription program through histone H3 tail proteolysis. Oncogene. 2022;41:560\u201370.","journal-title":"Oncogene"},{"key":"2956_CR36","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1128\/MCB.20.9.3058-3068.2000","volume":"20","author":"M Jaskelioff","year":"2000","unstructured":"Jaskelioff M, Gavin IM, Peterson CL, Logie C. SWI-SNF-mediated nucleosome remodeling: role of histone octamer mobility in the persistence of the remodeled state. Mol Cell Biol. 2000;20:3058\u201368.","journal-title":"Mol Cell Biol"},{"key":"2956_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0076-6879(03)75002-2","volume":"375","author":"PN Dyer","year":"2004","unstructured":"Dyer PN, Edayathumangalam RS, White CL, Bao Y, Chakravarthy S, Muthurajan UM, et al. Reconstitution of nucleosome core particles from recombinant histones and DNA. Methods Enzymol. 2004;375:23\u201344.","journal-title":"Methods Enzymol"},{"key":"2956_CR38","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/1878-0261.13652","volume":"18","author":"Y Shin","year":"2024","unstructured":"Shin Y, Kim S, Liang G, An W. MMP-9-dependent proteolysis of the histone H3 N-terminal tail: a critical epigenetic step in driving oncogenic transcription and colon tumorigenesis. Mol Oncol. 2024;18:2001\u201319.","journal-title":"Mol Oncol"},{"key":"2956_CR39","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766\u201373.","journal-title":"Nucleic Acids Res"},{"key":"2956_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"2956_CR41","doi-asserted-by":"publisher","first-page":"e23409","DOI":"10.1371\/journal.pone.0023409","volume":"6","author":"X Zhao","year":"2011","unstructured":"Zhao X, Valen E, Parker BJ, Sandelin A. Systematic clustering of transcription start site landscapes. PLoS ONE. 2011;6:e23409.","journal-title":"PLoS ONE"},{"key":"2956_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"key":"2956_CR43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02956-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:05:10Z","timestamp":1784675110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02956-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2956"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02956-3","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of University of Southern California, and were conducted in accordance with the committee\u2019s institutional guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"414"}}